“Influence of Baseline Demographics Disease Characteristics on Efficacy of an Oral Selective TYK2 Inhibitor, BMS-986165, in Patients With Moderate to Severe Plaque Psoriasis: Phase 2, Randomized, Placebo-Controlled Trial”. SKIN The Journal of Cutaneous Medicine, vol. 3, Nov. 2019, p. S14, https://doi.org/10.25251/skin.3.supp.14.